Clinical Trials Logo

Clinical Trial Summary

The present clinical trial is a prospective, investigator-initiated, single-arm, open-label, multicenter phase II trial investigating whether a definite organ preservation therapy consisting of the combination of durvalumab with chemoradiation is an efficient and safe treatment option for early stage, cT1 and cT2N0, esophageal adenocarcinoma with indication for radical surgery.


Clinical Trial Description

Patients with early stage, cT1 and cT2N0 esophageal adenocarcinoma with indication for radical surgery (esophagectomy or transhiatal extended gastrectomy) will be enrolled in two cohorts according to their PD-L1 CPS (cohort 1 CPS < 10, cohort 2 CPS ≥ 10). All patients will receive core treatment consisting of immunotherapy with durvalumab in parallel to 2 cycles FLOT chemotherapy, followed by immunotherapy with durvalumab in parallel to 3 cycles of modified FOLFOX plus concomitant radiation (50 Gy). Eight weeks after this, patients will undergo tumor assessment consisting of esophagogastroduodenoscopy with extensive biopsies (bite-on-bite biopsies and fine-needle aspiration), endoscopic ultrasonography with measurement of maximum tumor thickness, and CT- or MRI-scans for tumor re-evaluation. Surgical resection would be offered only to those patients in whom a locoregional persistence is confirmed on tumor assessment, in the absence of any signs of distant dissemination. Patients with complete remission will enter the maintenance phase receiving durvalumab monotherapy for up to 12 cycles. The primary objective of this trial is to investigate the treatment efficacy of the combination of durvalumab and chemoradiation as organ preservative treatment option avoiding mortality and surgical complications with rate of clinical and pathological complete response (cCR/pCR) at time of endoscopic re-evaluation defined as primary efficacy endpoint. The secondary objectives are the further assessment of the efficacy of the combination of durvalumab and chemoradiation as organ preservative treatment option 1-/2- and 3-year cCR/pCR rate, rate of salvage surgery, 90-day and 1-year mortality as secondary endpoints and to assess the quality of life (QoL). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05713838
Study type Interventional
Source Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Contact Thorsten Götze, Prof. Dr.
Phone +496976014187
Email goetze.thorsten@khnw.de
Status Recruiting
Phase Phase 2
Start date August 28, 2023
Completion date February 2027

See also
  Status Clinical Trial Phase
Withdrawn NCT05001360 - Study of FMT Combined With Nivolumab in Gastric Cancer N/A
Completed NCT03008980 - WATS3D for the Detection of Esophageal Dysplasia
Recruiting NCT04018872 - Evaluating the Effect of Itraconazole on Pathologic Complete Response Rates in Esophageal Cancer Phase 2
Recruiting NCT05476796 - Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer Phase 2
Recruiting NCT06030180 - CLUE: CLinical Utility Study of EsoGuard N/A
Active, not recruiting NCT04408105 - Survey Study on Barrett's Esophagus Screening
Completed NCT06381583 - A Liquid Biopsy for High-risk Pre-cancer Screening of Esophageal Adenocarcinoma
Recruiting NCT05591053 - Utility and Usability of ActivSight™ Laser Speckle Imaging in Visualization of Tissue Perfusion and Blood Flow During Esophageal Surgery in Humans N/A